DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that results from the Phase 3 clinical trial of Lymphoseek® (technetium Tc 99m tilmanocept) Injection in Head and Neck Cancer (NEO3-06) at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute were published in the current edition of the peer-reviewed journal, JAMA Otolaryngology Head and Neck Surgery, a publication of the American Medical Association. The publication, “Use of a Novel Receptor-Targeted (CD206) Radiotracer, 99m-Tc-Tilmanocept, and SPECT/CT for Sentinel Lymph Node Detection in Oral Cavity Squamous Cell Carcinoma: Initial Institutional Report in an Ongoing Phase 3 Study,” describes the experience at one of the clinical trial sites that participated in NE03-06, a Phase 3 study designed to assess the potential utility of Lymphoseek as a sentinel lymph node mapping agent in patients with head and neck cancer.
Help employers find you! Check out all the jobs and post your resume.
